Sana Biotechnology公司公布的最新研究数据显示，其开发的HIP修饰胰岛细胞在长达14个月的观察期内表现出优异的安全性特征、有效的免疫逃逸功能以及持续的胰岛素分泌能力。这项突破性进展为1型糖尿病细胞疗法领域带来了新的希望。
实验结果表明，经过基因编辑的胰岛细胞不仅能够规避宿主免疫系统的攻击，还能长期维持生理性胰岛素分泌功能。该技术平台通过创新性的免疫伪装机制，为解决移植排斥反应这一行业难题提供了全新思路。
研究人员指出，持续14个月的动物实验验证了HIP修饰技术的长期有效性，为后续临床研究奠定了坚实基础。这一成果标志着再生医学在代谢性疾病治疗领域取得重大突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.